Quilter Plc Lowers Stock Holdings in Pfizer Inc. $PFE

Quilter Plc cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 783,815 shares of the biopharmaceutical company’s stock after selling 54,878 shares during the quarter. Quilter Plc’s holdings in Pfizer were worth $19,517,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Mattern Wealth Management LLC boosted its position in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares during the last quarter. Peak Asset Management LLC raised its stake in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the period. Quest Investment Management LLC boosted its holdings in shares of Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the last quarter. Community Bank & Trust Waco Texas increased its holdings in shares of Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares during the last quarter. Finally, CVA Family Office LLC boosted its holdings in Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 413 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $28.37 on Monday. The firm has a market capitalization of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.75. The stock’s 50 day moving average price is $27.09 and its 200 day moving average price is $25.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the company earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Morgan Stanley set a $27.00 price target on Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.19.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.